Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + Cemiplimab vs Pembrolizumab as Adjuvant Therapy in Completely Resected High-risk Melanoma
2022-501576-25-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Fianlimab + Cemiplimab with Pembrolizumab (2 arms). Primary endpoint: Relapse-free survival. Planned start May 2023; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-501576-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501576-25-00.